NCT03607162 (DIAFEVER) is a NA clinical trial of DIAFEVER algorithm in Fever Without Source, sponsored by Nantes University Hospital.

Who is sponsoring NCT03607162?

NCT03607162 is sponsored by Nantes University Hospital.

What drugs are being tested in NCT03607162?

Interventions in NCT03607162: DIAFEVER algorithm.

What condition does NCT03607162 study?

NCT03607162 studies Fever Without Source.

Is NCT03607162 still recruiting?

NCT03607162 is currently completed. Last updated 21 December 2021.

Last reviewed 2021-12-21 · How we verify

NCT03607162: DIAFEVER

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Impact of a PCT(Procalcitonin) Rapid Test -Based Approach on ATB (Antibiotics) Use in Children With Fever Without Source

Completed NA Last updated 21 December 2021

What this trial tests

NA trial testing DIAFEVER algorithm in Fever Without Source in 4,928 participants. Completed in 3 December 2021.

Timeline

1 November 2018

Primary endpoint
3 December 2021

3 December 2021

Quick facts

Lead sponsor	Nantes University Hospital
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	single
Primary purpose	diagnostic
Enrollment	4,928
Start date	1 November 2018
Primary completion	3 December 2021
Estimated completion	3 December 2021
Sites	26 locations across France, Switzerland

Drugs / interventions tested

DIAFEVER algorithm

Conditions studied

Fever Without Source — all drugs for Fever Without Source →

Sponsor

Nantes University Hospital

Who can join

Adults 6 Days to 36 Months, any sex, with Fever Without Source. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Because a newly available point-of-care test may have real interest especially for children in the Emergency Department (ED) setting, by limiting painful and stressful venipunctures and decreasing the length of stay in the ED, the investigators hypothesize that integrating this new capillary Procalcitonin (PCT) rapid test in the DIAFEVER CPR (Clinical Prediction Rules) could represent a highly valuable diagnostic tool to identify a group with low Invasive Bacterial Infection (IBI) risk and could limit unnecessary exams and antibiotic prescriptions. The aim of this present study is to demonstrate the impact of this new PCT rapid-test-based CPR on antibiotic prescription rate in young children with Fever Without Source (FWS) presenting to the ED and on morbidity and mortality

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Assessment of the impact of a new sequential approach to antimicrobial use in young febrile children in the emergency department (DIAFEVERCHILD): a French prospective multicentric controlled, open, cluster-randomised, parallel-group study protocol.
Hubert G, Launay E, Feildel Fournial C, Chauvire-Drouard A, et al · · 2020 · cited 3× · PMID 32792425 · DOI 10.1136/bmjopen-2019-034828
Point-of-care decision rule for antibiotic prescriptions in young children with fever without source: an open cluster randomised trial.
Malorey D, Tavernier E, Drouard A, Vrignaud B, et al · · 2026 · PMID 41407517 · DOI 10.1136/archdischild-2025-329438

Verify or expand the search:

Other recruiting trials for Fever Without Source

Currently open trials in the same condition.

NCT07004751 — Etiology of Febrile Illness in Nepal (DEFINe Study) · NA · recruiting

Other Nantes University Hospital trials

Trials by the same sponsor.

NCT07278661 — Preoperative Use of Romiplostim in Thrombocytopenic Patients Undergoing Cardiac Surgery. · Phase 2 · recruiting
NCT06681363 — Creation of a Biocollection of Patients With Acute Myeloid Leukemia (AML) or Lymphoid Leukemia (ALL) or High-risk Myelod · not yet recruiting
NCT07467382 — GOAT (Gait Observation of Achilles Tendon) · not yet recruiting
NCT07490379 — Comparison of the Efficacy of Transcranial Direct Current Stimulation at Home Versus in Hospital Settings in Patients Wi · NA · not yet recruiting
NCT07423481 — Weight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03607162 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Nantes University Hospital
Last refreshed: 21 December 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03607162.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing